eurocognitive effects in patients with advanced prostate cancer treated with androgen deprivation therapy

• Conditions: C61; Malignant neoplasm of prostate

• Registration Number: DRKS00017727
• Lead Sponsor: niversitätsklinikum Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-05
• Study Completion: 2019-08-22
• Results First Posted: 2023-07-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

Patients with advanced prostate cancer
- Age: 45 - 85 years old
- visiting the urooncological doctor's consultation at the National Center for Tumor Diseases Heidelberg and/or being treated on site
- capacity to consent
- signed informed consent

Exclusion Criteria

- Insufficiant knowledge of the German language
- Neurological and/or psychiatric disorder
- Incorrectable visual impairment

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive Functioning<br><br>The neurocognitive assessment includes four tests of the Wiener Testsystem (WTS), Schuhfried GmbH:<br>- Wiener Wortflüssigkeitstest to measure lexical word fluency<br>- Auditiver Wortlisten Lerntest to measure some aspects of the patients' memory and learning ability<br>- Trail Making Test - Langensteinbacher Version to measure some aspects of executive functions<br>- N-back verbal, another instrument to measure some aspects of executive functions<br><br>Moreover, the subjective perception will be assessed using a questionnaire (Funcional Assessment of Cancer Therapy - Cognitive Function; FACT-Cog)

Secondary Outcome Measures

Name	Time	Method
Mental Health, measured with the Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P; questionnaire)